Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Two months of treatment with
rifampin and pyrazinamide is effective in preventing tuberculosis (TB) in
tuberculin-positive, human immunodeficiency virus (HIV)-seropositive individuals.1,2 Recent reports, however, have
raised concerns about the safety of rifampin and pyrazinamide for latent TB
infection in HIV-seronegative individuals, although toxicity incidence is
not known.3 The reported adverse events
have occurred with use of a daily regimen. We studied the outcomes of a twice-weekly
regimen of these medications to treat latent TB in 600 prison inmates in Maryland.
Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and Tolerability of Intermittent Rifampin/Pyrazinamide for the Treatment of Latent Tuberculosis Infection in Prisoners. JAMA. 2002;288(2):165-166. doi:10.1001/jama.288.2.162